White Circle’s AI Control Platform Raises $11m from Industry Giants After Founder Goes Viral for Exposing Safety Flaw in Biggest AI Models
12.5.2026 13:19:00 CEST | Business Wire | Press Release
White Circle – the platform trusted by global brands to keep their AI models in check – has raised $11m from some of the biggest names in the industry including Romain Huet (OpenAI); Dirk Kingma (ex-OpenAI, now Anthropic); Guillaume Lample (Mistral); Thomas Wolf (Hugging Face); Olivier Pomel (Datadog); François Chollet (Keras); Mehdi Ghissassi (ex-DeepMind); Paige Bailey (DeepMind); and David Cramer (Sentry). The Seed funding will be used to further accelerate product development, expand its team across the US, UK and Europe and grow White Circle's global customer base.
As firms look to capitalise on the AI boom; with vibe coding letting anyone ship AI products in an instant; and with increased reports of AI models breaking free from their safety rails, White Circle is the only all-in-one, enterprise-grade platform that tests, protects, observes and improves AI in real time.
It was founded by engineer Denis Shilov who went viral in 2024 when he bypassed the safety filters of every major AI model with a single prompt. Shilov’s universal jailbreak meant he could unlock instructions on how to make drugs and weapons, access dangerous or illegal information and extract anything that models including ChatGPT, Claude and more were explicitly built to refuse.
After hitting 1.4M views, the post drew attention from Anthropic, OpenAI and Hugging Face, leading to Shilov being invited to join Anthropic’s bug bounty program and later building the White Circle platform to meet growing demand from AI providers.
A single source of truth and trust
White Circle’s proprietary models monitor AI inputs and outputs in real time. Based on each company’s custom policies, they detect harmful content, catch hallucinations, prevent prompt injection attacks, flag model drift and identify abusive or malicious users. The data from these scans helps teams understand how their models perform in different use cases, making it easier to choose the right models and improve them over time. Everything runs through a single API.
In practice, White Circle can detect a fintech model leaking sensitive customer data, block an AI agent from executing malicious instructions like deleting files or disrupting systems, flag and ban users attempting to abuse the system, and spot rising user frustration when a model starts to fail. Teams can define custom policies to control exactly what is allowed based on their needs, including automated enforcement actions like rate limiting or banning bad actors. The models also improve over time by learning from labelled user feedback, becoming more accurate and better adapted to each use case. Support for 150 languages ensures it works reliably across global products.
The platform itself is led by Head of Design Elena Iumagulova. White Circle is also SOC 2 Type I and Type II certified and HIPAA compliant.
"AI is moving faster than our ability to guide it," said Denis Shilov, founder and CEO of White Circle. "We already trust it with decisions that touch millions of people – from hiring to healthcare, finance and security – and with the rise of vibe coding, anyone can ship an AI product without knowing what that model is actually doing once it's live. Until now there’s not been a platform purpose-built to monitor AI’s behaviour, catch it when it goes wrong, or shape how it acts. With White Circle, we’re finally giving companies everything they need to hold their AI accountable and optimise their models in a single place, without sacrificing security, compliance or risk.”
Elena Iumagulova, Head of Design at White Circle said: “We wanted any team, technical or not, to be able to see exactly what their AI is doing in one place – whether they're getting visibility into their models for the first time or running AI at scale and need to catch problems fast. Everything from real-time flagging to analytics and optimisation lives in one place, connected via a single API."
Keeping AI accountable
As part of its mission to close AI's accountability gaps, White Circle’s research continues to shape how the industry understands model risk. In May 2025, the company published CircleGuardBench, a benchmark that tests how well AI moderation models actually perform under real-world conditions. This benchmark lets anyone search by model and see their performance.
More recently, the company published its KillBench study in which it ran more than a million experiments across 15 AI models, including those from OpenAI, Google, Anthropic, and xAI, to uncover hidden biases. When forced to make decisions about human lives, all models showed preferences depending on nationality, religion, body type, and even phone brand. The research also found that structured output, the standard integration method for production AI, repeatedly caused refusal rates to collapse and biases to amplify.
"Denis and the White Circle team have an unusual combination of deep technical credibility and a clear commercial instinct," said Ophelia Cai, Partner at Tiny VC. "The KillBench research alone shows what's possible when you approach AI safety empirically rather than ideologically and the team is building the infrastructure the industry genuinely needs."
ENDS
About White Circle
White Circle is an AI control platform that helps companies monitor, protect, and improve AI models in production. Its platform checks inputs and outputs against custom policies, detects hallucinations and prompt injection, and provides real-time analytics on model behaviour. White Circle is SOC 2 and HIPAA compliant and supports more than 150 languages. Visit whitecircle.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20260512448166/en/
Contacts
Aimee Soulsby
aimee@burlington.cc
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom